The Role of 68Ga-FAPI PET/CT in Detection of Metastatic Lobular Breast Cancer. (14th March 2023)

• Record Type: Journal Article
• Authors: Eshet, Yael; Tau, Noam; Apter, Sara; Nissan, Noam; Levanon, Keren; Bernstein-Molho, Rinat; Globus, Ofer; Itay, Amit; Shapira, Tal; Oedegaard, Cecilie; Gorfine, Malka; Eifer, Michal; Davidson, Tima; Gal-Yam, Einav; Domachevsky, Liran
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 3(2023)
• Page Start: 228
• Page End: 232
• Publication Date: 2023-03-14
• Subjects: breast neoplasms -- carcinoma -- FAPI-04 -- lobular -- PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004540
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Purpose: Invasive lobular breast cancer (ILC) may be hard to detect using conventional imaging modalities and usually shows less avidity to 18 F-FDG PET/CT. 68 Ga–fibroblast activation protein inhibitor (FAPI) PET/CT has shown promising results in detecting non– 18 F-FDG–avid cancers. We aimed to assess the feasibility of detecting metastatic disease in patients with non– 18 F-FDG–avid ILC. Methods: This prospective study included patients with metastatic ILC, infiltrative to soft tissues, which was not 18 F-FDG avid. The patients underwent 68 Ga-FAPI PET/CT for evaluation, which was correlated with the fully diagnostic CT performed at the same time. Results: Seven women (aged 57 ± 10 years) were included. Among the 30 organs and structures found to be involved by tumor, the number of findings observed by FAPI PET/CT was significantly higher than that observed by CT alone ( P = 0.022), especially in infiltrative soft tissue and serosal locations. Conclusions: This small pilot trial suggests a role for 68 Ga-FAPI PET/CT in ILC, which needs to be confirmed by subsequent trials.